IGF2BP3 and thyroid cancer: In conclusion, the expression of SETMAR in thyroid cancer is stabilized by METTL3‐mediated m6A modification in an IGF2BP3‐dependent manner, which could explain its dysregulation during dedifferentiation of thyroid cancer.